Dimemebfe (5-MeO-BFE) is both a recreational drug and a research chemical. This compound functions as an agonist for the serotonin receptors within the 5-HT1A and 5-HT2 families. Structurally, it bears a resemblance to the psychedelic tryptamine derivative 5-MeO-DMT, albeit with a notable difference – the substitution of the indole nitrogen with oxygen, thus categorizing dimmable as a benzofuran derivative. While it retains certain similarities, it exhibits significantly reduced potency as a serotonin agonist when compared to 5-MeO-DMT. Notably, dimmable displays relatively stronger activity at 5-HT1A receptors, but its primary effects are still most prominent at the 5-HT2 family of serotonin receptors.

IUPAC name
CAS Number140853-58-3 
PubChem CID126589
CompTox Dashboard (EPA)DTXSID80161481
Chemical and physical data
Molar mass219.284 g·mol−1

Legal status

Dimemebfe has been classified as a Schedule I controlled substance within the state of Alabama in the United States.


1. What is Dimemebfe?

  • Dimemebfe is a synthetic compound that is classified as a research chemical and has been used recreationally. It shares structural similarities with other psychoactive substances.

2. Is Dimemebfe legal?

  • The legal status of Dimemebfe varies by country and jurisdiction. In some regions, it is classified as a controlled substance, while in others, it may be unregulated or in a legal gray area. It’s important to understand the specific regulations in your area.

3. How does Dimemebfe compare to other substances like 5-MeO-DMT?

  • Dimemebfe is structurally related to 5-MeO-DMT but has unique effects and characteristics. It may differ in terms of its potency and receptor interactions.

4. What are the potential effects of Dimemebfe?

  • Dimemebfe is known for its psychoactive effects, including altered perception, changes in consciousness, and hallucinogenic experiences. The specific effects can vary from person to person.

5. Is Dimemebfe safe to use?

  • The safety and long-term effects of Dimemebfe have yet to be extensively studied. As with any research chemical or psychoactive substance, using it responsibly and cautiously is crucial, particularly given the limited research available.

6. Are there any risks associated with Dimemebfe use?

  • Using Dimemebfe, like other psychoactive substances, carries potential risks, including psychological distress, anxiety, and other adverse effects. Careful consideration of set and setting is essential.

7. How is Dimemebfe typically consumed?

  • Dimemebfe can be ingested through various methods, including oral consumption or other routes, depending on its form. It is essential to follow responsible dosing practices.

8. Can Dimemebfe be used for therapeutic purposes?

  • There is limited research on the therapeutic potential of Dimemebfe, and it is not approved for any medical or therapeutic use. Other substances, like psilocybin and MDMA, have been more extensively studied for therapeutic applications.

9. Is Dimemebfe addictive?

  • The addictive potential of Dimemebfe is not well understood, but it is generally considered to have a lower risk of physical dependence compared to substances like opioids or stimulants. Psychological dependence, however, can still occur.

10. Where can I find more information about Dimemebfe?

  • Given the evolving legal and scientific landscape surrounding Dimemebfe, it’s important to consult reliable sources of scientific literature and seek advice from healthcare professionals. Staying informed and making well-informed decisions is crucial when considering the use of this substance.


  1. In the Microgram Journal, researchers Casale JF and Hays PA conducted a study titled “The Characterization of 2-(5-Methoxy-1-benzofuran-3-yl)-N,N-dimethylethanamine (5-MeO-BFE) and Differentiation from its N-Ethyl Analog.” This research, documented in Volume 9, Issue 1, spans pages 39 to 45.
  2. In May 1992, Tomaszewski Z, Johnson MP, Huang X, and Nichols DE contributed to the study “Benzofuran bioisosteres of hallucinogenic tryptamines,” published in the Journal of Medicinal Chemistry (Volume 35, Issue 11, Pages 2061-2064). This research explores compounds related to hallucinogenic tryptamines and their structural similarities.
  3. In March 2014, the “Alabama Senate Bill 333” addressed the classification of controlled substances. It included additional synthetic controlled substances and analogue substances in Schedule I, and it pertained to issues such as trafficking in controlled substance analogues. This legislation increased the requisite weight for certain elements. The source was retrieved on September 28, 2015.

Leave a Comment

Your email address will not be published. Required fields are marked *